A strategy for encapsulating peritoneal sclerosis: pay attention not only to PD solution but also middle molecular uraemic substances retention!
Yokoyama
Keitaro
K
Hosoya
Tatsuo
T
D015314:Dialysis Solutions / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D056627:Peritoneal Fibrosis / Q000150:complications*; D014118:Toxins, Biological / Q000009:adverse effects*; D014511:Uremia / Q000209:etiology
D015314:Dialysis Solutions; D014118:Toxins, Biological; C026865:uremia middle molecule toxins